Li Y-L, Zheng M-X, Wang G
Department of Hepatopancreatobiliary and Spleen Surgery, Baoji Central Hospital, Baoji, Shaanxi Province, P.R. China.
Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4266-4273.
This work aimed to identify disturbed pathways in hepatitis C virus (HCV)-cirrhosis with hepatocellular carcinoma (HCC) based on individualized pathway aberrance score (iPAS) method.
First of all, gene expression data and pathway data were recruited and preprocessed. Next, iPAS method, which contained three steps (gene-level statistics based on average Z algorithm, pathway-level statistics and pathway significant analysis based on Wilcoxon-test), was performed to identify differential pathways in HCV-cirrhosis with HCC. Then, a protein-protein interaction (PPI) network was conducted based on the genes enriched in the differential pathways. Finally, topological analysis of the PPI network combined with cancer genes was conducted to identify hub disease genes.
After a systematic operation by the iPAS method, a total of 34 differential pathways were identified (p-value < 0.01). From the PPI network that was constructed using the 243 genes in the differential pathways, a total of 24 hub genes were obtained by conducting degree centrality, and 4 hub cancer genes (UBC, MAPK1, NOTCH1 and RHOA) were identified. An in-depth analysis indicated that NF-kB is activated and signals survival pathway contained the most cancer genes (number = 7), in which there was a hub cancer gene UBC. In addition, as we set the p-value in ascending order, we found that opioid signaling pathway was the most significant pathway (p = 1.59E-06), and hub cancer gene MAPK1 was enriched in this pathway.
The altered pathways and several key genes identified by this method were predicted to play important roles in HCV-cirrhosis with HCC and might be potentially novel predictive and prognostic markers for HCV-cirrhosis with HCC.
本研究旨在基于个体通路异常评分(iPAS)方法,识别丙型肝炎病毒(HCV)肝硬化合并肝细胞癌(HCC)中紊乱的通路。
首先,收集并预处理基因表达数据和通路数据。接下来,采用iPAS方法(包括基于平均Z算法的基因水平统计、通路水平统计以及基于Wilcoxon检验的通路显著性分析三个步骤)来识别HCV肝硬化合并HCC中的差异通路。然后,基于差异通路中富集的基因构建蛋白质-蛋白质相互作用(PPI)网络。最后,结合癌症基因对PPI网络进行拓扑分析,以识别枢纽疾病基因。
通过iPAS方法进行系统操作后,共识别出34条差异通路(p值<0.01)。利用差异通路中的243个基因构建PPI网络,通过度中心性分析共获得24个枢纽基因,并识别出4个枢纽癌症基因(泛素C(UBC)、丝裂原活化蛋白激酶1(MAPK1)、Notch信号通路蛋白1(NOTCH1)和RhoA小G蛋白(RHOA))。深入分析表明,核因子κB(NF-κB)被激活,信号生存通路包含的癌症基因最多(数量=7),其中有一个枢纽癌症基因UBC。此外,当我们按p值升序排列时,发现阿片类信号通路是最显著的通路(p = 1.59E-06),枢纽癌症基因MAPK1富集于该通路。
该方法识别出的改变的通路和几个关键基因预计在HCV肝硬化合并HCC中起重要作用,可能是HCV肝硬化合并HCC潜在的新型预测和预后标志物。